GenSight Biologics Announces the Filing of its 2016 Registration Document

GenSight Biologics to Present GS010 at the 4th Annual Retinal Cell & Gene Therapy Innovation Summit

GenSight Biologics to Present GS010 at the 2017 Annual Meeting of the American Academy of Neurology

GenSight Biologics to Attend Upcoming Investor Conferences

GenSight Biologics to Present Data on GS010 at the 43rd Annual Meeting of NANOS

GenSight Biologics Reports Full Year 2016 Financial Results

GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy

GenSight Biologics receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa

GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

GenSight Biologics reports its cash position as of September 30, 2016